You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

Mass. Movers

Insiders boosting their stake in Aegerion

Aegerion develops drugs to treat rare diseases.

Aegerion develops drugs to treat rare diseases.

Continue reading below

The Motley Fool, noting one way to forecast a stock’s direction is to monitor insiders’ share purchases, reported that Cambridge-based Aegerion Pharmaceuticals Inc. has seen “significant insider and institutional interest.” In the last 6 months, insiders have acquired an additional 624,767 shares, bringing total insider holdings to 5.8 million shares, an 11 percent increase. During the same time, institutions increased their holdings by 2.1 million shares, or 10 percent.

Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of